A panelist discusses how clinicians are navigating the evolving landscape of multiple myeloma treatment, from considering early intervention in high-risk smoldering cases to personalizing initial ...
Hans Lee, MD, explores how minimal residual disease (MRD) testing guides treatment decisions for multiple myeloma and highlights the value of patient preferences.
Foundever, a customer experience (CX) services and solutions provider, is collaborating with M47 Labs, an artificial intelligence solutions provider, to support the continued development of its LLM ...